Compare DOX & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOX | TNGX |
|---|---|---|
| Founded | 1982 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 4.5B |
| IPO Year | 1998 | 2020 |
| Metric | DOX | TNGX |
|---|---|---|
| Price | $58.55 | $26.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $92.33 | $21.78 |
| AVG Volume (30 Days) | 1.3M | ★ 2.0M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.56% | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $62,384,000.00 |
| Revenue This Year | $4.48 | N/A |
| Revenue Next Year | $3.76 | N/A |
| P/E Ratio | $13.65 | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $49.74 | $6.25 |
| 52 Week High | $90.29 | $34.39 |
| Indicator | DOX | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 64.94 | 53.56 |
| Support Level | $49.81 | $27.79 |
| Resistance Level | $64.77 | $33.96 |
| Average True Range (ATR) | 1.87 | 1.59 |
| MACD | 0.72 | 0.11 |
| Stochastic Oscillator | 91.16 | 74.59 |
Amdocs Ltd is a provider of software and services to communications, entertainment, and media service providers. The Company operates in a single segment and designs, develops, markets, supports, implements, and operates open and modular cloud offerings. Its portfolio includes solutions across digital business systems and legacy business and operational support systems, supporting multiple lines of business such as wireless, broadband, cable, fiber, satellite, and digital services. The Company leverages artificial intelligence to support digital transformation, cloud adoption, and intelligent network automation. Geographically, it derives a majority of its revenue from North America and also operates in Europe and the rest of the world.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.